Introduction
Normal tissue homeostasis requires constant regulation of cell growth and cell death. Recent evidence implies that the failure of cells to undergo apoptotic cell death may in¯uence the pathogenesis of various human diseases, including cancer, autoimmune diseases, and viral infections (Thompson, 1995) . Bcl-2 and its related cytoplasmic proteins are key regulators of apoptosis. At least 15 Bcl-2 family members have been identi®ed in mammalian cells, and either inhibit (e.g., Bcl-2, B¯-1, Bcl-x L , and Mcl-1) or promote cell death (e.g., Bax, Bik, and Bad) (Adams and Cory, 1998) . All prosurvival bcl-2-like genes are oncogenic because they provide a growth advantage that may eventually lead to neoplastic transformation. Indeed, overexpression of Bcl-2, B¯-1, Bcl-x L , and Mcl-1 proteins have been noted in lymphoma, mast cell leukemia, multiple myeloma, gastric cancer, neuroblastoma, and prostate cancers (Schlaifer et al., 1995; Cervero et al., 1999; Choi et al., 1995; Dole et al., 1995; Krajewska et al., 1996) . These ®ndings re¯ect the important concept that apoptosis regulation by altering the level of Bcl-2 family proteins may contribute to neoplastic development (Chao and Korsmeyer, 1998) . No doubt exists that clarifying the cellular factor(s) responsible for regulating Bcl-2 family proteins is an urgent task.
Interleukin-6 (IL-6), originally identi®ed as a B-cell dierentiated factor, is a multifunctional cytokine on various tissues and cells (Kishimoto, 1989) . IL-6 regulates immune and in¯ammatory responses, hepatic acute-phase protein synthesis, hematopoiesis, and bone metabolism through its speci®c binding receptor (IL-6-Rp80) and signal transducer gp130 (Kishimoto et al., 1995) . IL-6 is also important in regulating tumor cell growth, and can be produced by various types of cancer cells, including multiple myeloma, renal cell carcinoma, prostate carcinoma, ovarian carcinoma, and cervical carcinoma by autocrine and/or paracrine mechanisms (Kawano et al., 1988; Miki et al., 1989; Okamoto et al., 1997; Wu et al., 1992; Eustace et al., 1993) .
IL-6 can act as an apoptosis inducer or inhibitor depending upon the types of cells (Kawano et al., 1988; Nakashima et al., 1999) . The anti-apoptotic genes bcl-x L and mcl-1, which were correlated with the status of the multiple myeloma, were found to be up-regulated by IL-6 in clinical multiple myeloma tissues and cell lines (Puthier et al., 1999b) . Furthermore, the activation of JAK/STAT3 pathway was preferentially required for IL-6-induced bcl-x L and mcl-1 gene expression in human multiple myeloma cells (CatlettFalcone et al., 1999; Puthier et al., 1999a) . However, current knowledge of the regulation mechanism of survival signaling elicited by IL-6 is largely restricted to cells of hematopoietic origin.
Cervical cancer is a leading cause of cancer-related deaths among women worldwide (Ponten et al., 1995) . Epidemiologic and laboratory data suggest that cervical cancer typically arises from a series of causal steps including, HPV infections, oncogenes expression (e.g., c-MYC, Ha-RAS, and ERB-2) and/or upregulation of pro-in¯ammatory cytokines (Pinion et al., 1991; Tartour et al., 1994 Tartour et al., , 1999 . IL-6 has been reported to in¯uence the pathogenesis of cervical cancer, because IL-6 is a central pro-in¯ammatory cytokine involved in female genital infection and because cervical cancer frequently develops in close association with chronic in¯ammation caused by infection with various sexually transmitted agents (Richter et al., 1999) . Additionally, IL-6 was found to be highly expressed in invasive cervical carcinoma, but either not expressed or only barely expressed in normal cervixes or in pre-neoplastic lesions (Tartour et al., 1994) . This study attempts to elucidate the role of IL-6 in the development of cervical cancers, with emphasizing its regulation of apoptosis. Our data indicate that IL-6 and Mcl-1 are co-expressed in human cervical cancer tissues and cell lines. Furthermore, IL-6 treatment eectively inhibits apoptosis of cervical cancer cells through induction of Mcl-1 via a PI 3K/Akt-dependent pathway.
Results
Concomitant expression of Mcl-1 and IL-6 in cervical cancer tissues and cell lines Tumor specimens randomly selected from patients with invasive cervical cancer were immunohistochemically stained with various antibodies speci®c to anti-Bcl-2 family proteins, including Bcl-2, Bcl-x L , and Mcl-1. In normal uterine cervix, Mcl-1 immunostaining was weakly present in mature super®cial squamous epithelial cells, but not in other cell types ( Figure 1a) . Meanwhile, in invasive squamous cell carcinoma, diuse and strong immunostaining was observed in the neoplastic cells for Mcl-1 proteins (Figure 1b) . In contrast, no apparent immunoactivity of Bcl-2 was detected in either the neoplastic cells or the normal cervical epithium, but positive immunostaining of Bcl-2 occurred in the lymphocytes of stroma (Figure 1c ). For Bcl-x L , a mild but homogenous immunostaining was distributed in the basal cells of normal squamous epithelium (Figure 1d ). Meanwhile, in squamous carcinoma, Bcl-x L immunostaining also displayed a weak but heterogenous pattern (Figure 1e) . The above observations suggest that Mcl-1, but not Bcl-2 or Bclx L , appeared to have higher levels in human cervical cancer tissues than in normal cervix tissues.
Our previous investigation also showed that IL-6 levels were signi®cantly increased in cervical cancer tissues (Wei et al., 2001) , prompting us to investigate the possible relationship between the expression of IL-6 and Mcl-1. To address this issue, six randomly selected biopsies from invasive cervical cancer patients, and ®ve independent cervical cancer cell lines, were employed to analyse the level of IL-6 and Bcl-2 family proteins using Western blotting. According to Figure 2a , a strict correlation exists between the levels of IL-6 and Mcl-1 in these six cervical cancer tissues, whereas the expression of other Bcl-2 family proteins, such as Bcl-x L and Bax, is not correlated with the IL-6 level. Bcl-2 proteins could not be detected in the tumor specimen. Notably, the level of IL-6 and Mcl-1 proteins was extremely low and could not be detected in normal epithelial counterparts (data not shown).
Subsequently, whether the close relationship between the expression of IL-6 and Mcl-1 could also be observed in the human cervical cancer cell model was determined. Two cell lines, C33A and MS751, which produced little or no IL-6 (550 pg/ml), also displayed an extremely low level of Mcl-1 (Figure 2b) . In contrast, cell lines including SiHa, HeLa and HT3, which secreted large amounts of IL-6 (750 ± 3000 pg/ ml), displayed higher levels of Mcl-1 (Figure 2b) . Interestingly, the expression of other Bcl-2 family proteins did not dier in these cancer cell lines.
These experimental results indicate that a highly coordinated expression of IL-6 and Mcl-1 was observed in both the clinical tumor specimen and the in vitro cell systems.
IL-6 regulates Mcl-1 expression in human cervical cancer cells
Whether IL-6 directly regulates the expression of Mcl-1 in human cervical cancer cells was explored next. Initially, C33A cells, a cell line which lacks IL-6 secretion, were serum starved for 48 h, then treated with 50 ng/ml of IL-6 for varying time periods. Western blotting revealed that upon IL-6 treatment, the level of Mcl-1 protein rapidly increased at 2 h, peaked at 4 ± 8 h (approximately 5 ± 6-fold), and then declined after 10 h (Figure 3a ). Meanwhile, the expression level of the other Bcl-2 family protein, Bax, was not aected by IL-6. Whether the level of Mcl-1 changed with varying concentrations of IL-6 was further investigated. Upon stimulation with 1 ng/ml of IL-6, the level of Mcl-1 increased signi®cantly, to around 2.5 times the level in the control cells ( Figure  3b) . Meanwhile, the expression of Mcl-1 was maximized at a concentration of 10 ng/ml (Figure 3b ). To address the same question, another experiment was designed to interrupt the autocrine loop of IL-6 in the SiHa cells and examine its aect on the level of Mcl-1 protein.
To interrupt IL-6 autocrine machinery, SiHa cells were exposed to dierent antibodies that could either speci®cally neutralize cytokine IL-6 or target the a chain of IL-6 receptor. As illustrated in Figure 3c when SiHa cells were incubated with either anti-IL-6 antibody or anti-IL-6 receptor a-chain antibody, it caused a reduction of approximately 50 ± 60% in endogenous Mcl-1 level. However, treatment with control antibody IgG did not in¯uence the level of Mcl-1 in the SiHa cells. In addition to the SiHa cells, the endogenous Mcl-1 level of the HeLa and HT-3 cells could also be partially attenuated by treatment with anti-IL-6 antibody (data not shown).
Based on the above results, we hypothesize that IL-6 functions as an autocrine factor that regulates the cellular level of Mcl-1 in human cervical cancers. Mcl-1 up-regulation was examined. To examine this issue, control vector and STAT3 dominant-negative mutant (STAT3F), in which Tyr-705, a phosphoacceptor site of STAT3, was mutated to phenylalanine (Nakajima et al., 1996) , were introduced into C33A cells. Stable expression of STAT3F resulted in inhibition of the endogenous STAT3 function, as evidenced by the decreasing of phosphorylated STAT3 with a speci®c anti-phospho-STAT3 antibody ( Figure  4a ). However, the IL-6-mediated up-regulation of Mcl-1 was not aected in neo control or STAT3F cells (Figure 4b ), suggesting that STAT3 is not involved in IL-6-stimulated Mcl-1 up-regulation in cervical cancer C33A cells. Whether the remaining two signaling pathways, MAPK and PI 3-K, were required for IL-6-induced Mcl-1 expression was also examined. To address this, two chemical inhibitors PD98059 and LY294002, which speci®cally inhibit MEK1 and PI 3-K respectively, were used. As Figure 4c , upper blot, veri®es, the IL-6-induced increase of phosphorylated ERK, as expected, was reduced by treatment with 25 or 50 mM PD98059. Whereas PD98059 did not aect IL-6 mediated up-regulation of Mcl-1 (Figure 4c , lower blot).
As 
IL-6-overexpressing cells confers resistance to apoptosis
To determine the exact role of IL-6 in human cervical cancer cells, the IL-6 expressing vector (pCMV-IL-6) and control vector (pCMV) were transfected into human C33A cells. Following transfection, cells were cultured in a medium containing 600 mg/ml of G418. Each colony that grew after G418 selection was picked and expanded. The C33A cells transfected with the IL-6 expression vectors were designated as C33A/IL-6 cells (C33A/IL-6-cl-5), with a vector control of C33A/ neo. ELISA analysis con®rmed that these IL-6-overexpressing clones produced substantially high levels of IL-6 (42000 pg/ml) than neo control cells (550 pg/ml) (Figure 5a) . Furthermore, the amounts of IL-6 receptor were quanti®ed by using immunoblotting with an antibody, which recognized the ligand binding subunit of the IL-6 receptor. However, neither the IL-6- /ml) were treated with 50 ng/ ml IL-6 for dierent periods of time (0, 2, 4, 6, 8, and 10 h) or treated with various concentrations of IL-6 (0, 1, 10, 50, and 100 ng/ml) for 6 h. After treatment, total proteins were extracted and the levels of Mcl-1 were determined by Western blotting. Relative intensities were quantitated by densitometer. (c) Interruption of IL-6 autocrine loop in SiHa cells lead to an attenuation of Mcl-1 level. Serum-starved SiHa cells (5610 5 /ml) were treated with anti-IL-6 (50 and 100 ng/ml), anti-IL-6 receptor a chain (100 ng/ml), or control IgG (100 ng/ml) antibody for 24 h. The expression of Mcl-1 and Bax protein was determined by immunoblotting and the relative intensities were quantitated by densitometer overexpressing cells nor the neo control cells caused any change in the level of IL-6 a-chain receptor ( Figure  5b ). Compatible with IL-6 levels, immunoblotting showed that these IL-6 transfectants did indeed display a higher level of Mcl-1 protein than the neo control cells (Figure 5c ). The data from the IL-6 transfectants is consistent with the results from exogenous IL-6 treatment (as shown in Figure 3a ,b) revealing that IL-6 can directly regulate the expression of Mcl-1. These IL-6-overexpressing clones have been examined their growth properties by determining MTT assay. No signi®cant dierence exists in growth rate between IL-6 transfectants and neo control cells (data not shown).
To explore the anti-apoptotic eect of IL-6, C33A/ IL-6-c5, C33A/neo, or parental C33A cells were treated with 3.5 mM of doxorubicin for 24 h. The characteristic morphology of apoptosis was subsequently determined by staining with Hoechst 33258. As illustrated in Figure  6a I ± VI, the typical apoptotic morphologies including, chromatin condensation and nuclear fragmentation, were clearly observed in neo control cells after treatment with doxorubicin, but not in IL-6-overexpressing cells (C33A/IL-6-c5). Furthermore, MTT colormetric analysis was also employed herein to determine the general cell survival of IL-6-overexpressing C33A clones (c1 and c5) and control cells. IL-6-overexpressing cells consistently exhibited much more resistance to various concentrations of cisplatin treatment than neo control cells (Figure 6b) . The above experimental results suggest that IL-6-overexpressing C33A cells exhibited a marked resistance to drugs, which may mediate through the inhibition of apoptosis.
Finally, it is interesting to elucidate the contribution of Mcl-1 in the anti-apoptotic eect of IL-6. To clarify /ml) were pre-treated with LY294002 (25 or 50 mM) for 1 h before IL-6 (50 ng/ml) was added. After further 60 min incubation, total proteins were extracted and the expressions of phosphoAkt and Akt were determined by Western blotting. (f) Dominant-negative Akt (dn-Akt) inhibits IL-6-induced Mcl-1 up-regulation. C33A cells were transfected with dnAkt or control vectors. After G418 selection, cells stably expressed dnAkt or neo control were treated with IL-6 (50 ng/ml) or none for 6 h. Cell lysates were subjected to SDS ± PAGE and analysed by Western blot using antiMcl-1 and anti-Bax antibodies the contribution of Mcl-1, this study attempts to establish a stable clone that could constitutively express the antisense mcl-1 in C33A/IL-6-c5 cells. However, no stable clones that survived and could express antisense mcl-1 were obtained, and thus a transient-transfection death assay was conducted. C33A/IL-6-c5 cells were cotransfected with GFP expression plasmid (pCMV-GFP) plus either empty vectors (pCDNA3) or antisense mcl-1 vectors. Forty-eight hours after transfection, transfected cells were transferred to a serum-free medium containing doxorubicin for a further 24 h. After treatment, the extent of cell death was determined based on the number of surviving cells expressing GFP¯uorescence. As Figure 7a displays, transfection of the antisense mcl-1 vector, but not the control vector, increased the sensitivity of C33A/IL-6-c5 cells to doxorubicin. Supporting this observation, the antisense mcl-1 transfection also eectively reduced the endogenous level of Mcl-1 in C33A/IL-6-c5 cells (Figure 7b ). These ®ndings suggest that IL-6 regulated the anti-apoptotic mechanism in human cervical cancer cells primarily through up-regulation of Mcl-1.
Discussion
Using an immunohistochemical approach, the current results show that Mcl-1 is the most abundant antiapoptotic proteins among Bcl-2 family members in human cervical cancer tissues. Mcl-1 and Bcl-2 are expressed at dierent stages of dierentiation in numerous normal tissues. These two proteins commonly appeared in gradients with opposing directions, such that the expression of Bcl-2 tended to be higher in the less dierentiated cells lining the basement membrane whereas Mcl-1 was more intense in the dierentiated cells . These ®ndings imply that the expressions of the Mcl-1 and Bcl-2 proteins are mutually exclusive. Thus, it is not surprising that Mcl-1 expression is more widespread in cervical cancer than Bcl-2 since most cervical cancers are, histologically, well-dierentiated, large cell type squamous cell carcinomas (Robert and Fu, 1990) . Although immunohistochemical staining does not provide actual quantitative data for target proteins, it can be utilized to distinguish which type of cells are positive for such an expression. The quantitative data from Western blotting (see Figure  2a) clearly revealed that the level of Mcl-1 protein is much higher than that of other Bcl-2 family members in cervical cancer specimens. Other investigators obtained a similar ®nding (Crawford et al., 1998) , namely that Mcl-1 expression was positive in 57% of primary and 75% of recurrent cervical cancers.
Mcl-1 was originally identi®ed as an early gene induced during dierentiation of ML-1 human myeloblastic leukemia cells (Kozopas et al., 1993) . Unlike Bcl-2, Mcl-1 contains a PEST sequence, which probably presents itself as a labile protein with an estimated half-life of 1 ± 3 h (Yang et al., 1995) . The intracellular distribution and pattern of expression of Mcl-1 overlap with those of Bcl-2 with a prominent mitochondrial localization, indicating they share the similar function of delayed apoptotic cell death (Yang et al., 1995) . Indeed, the role of Mcl-1 in preventing Overexpression of IL-6 in C33A against cisplatin cytotoxicity. C33A/IL-6-cl, c5, neo, and parental C33A cells were exposed to various concentrations of cisplatin for 24 h. Then, the survived cells were ®xed and subjected for MTT colorimetric analysis. The means (bars, s.d.) were calculated from at least three independent experiments for each sample cell death was ®rst demonstrated in Chinese hamster ovary cells undergoing apoptosis in response to c-myc over-expression (Reynolds et al., 1994) . Similarly, Mcl-1 can interacting with Bax in hematopoietic FDC-P1 cells and can prolong cell viability under various cytotoxic conditions (Zhou et al., 1997) . Additionally, it has been proven that mcl-1 is tightly regulated by the GM-CSF signaling pathway and is one component of the GM-CSF viability response Moulding et al., 1998) . However, the above studies almost all focused on hematepoietic cell systems. The present investigation is the ®rst to demonstrate that Mcl-1 is also critical in overriding apoptotic cell death in human cervical cancer cells.
Recently, many investigators have considered the possible role of IL-6 in the pathogenesis of human cervical cancers (Castrilli et al., 1997; Tjiong et al., 1999) , but they made little progress. The lack of progress most likely results from the downstream eector of IL-6 remaining unidenti®ed. The present study provides a novel ®nding, namely that in¯ammatory cytokine IL-6 can up-regulate the expression of Mcl-1, as evidenced by the coexpression of IL-6 and Mcl-1 in the tumor specimen and in in-vitro cell model. Our previous investigations (Wei et al., 2001) have demonstrated that IL-6 and its a-chain receptor are over-expressed in human cervical cancer tissues but not in their normal counterparts, suggesting that IL-6 is an autocrine factor in human cervical cancer. Besides, tumor size is closely correlated with the level of IL-6. Results of the present study at least partially support previous clinical observations, namely that overexpression of IL-6 rendered cervical cancer cells is more refractory to apoptosis (Figure 5a ). The increase of the apoptosis threshold in cervical cancer cells with IL-6 armed them against attack by immune cells and allowed preneoplastic or neoplastic cells to maintain their growth. Supporting the above ®ndings, IL-6 has been found to be crucial to the oncogenesis of human multiple myeloma (Kawano et al., 1988) . The anti-apoptotic Mcl-1 protein was also tightly regulated by IL-6 in human multiple myeloma cells (Puthier et al., 1999b) .
Binding of IL-6 and its receptor triggers the recruitment of the signal-transducing protein gp130, and subsequently activates JAK/STAT or Ras/MAP kinase pathways, which have been implicated in the survival and/or proliferation of multiple myeloma (Catlett-Falcone et al., 1999; Ogata et al., 1997) . Further study showed that IL-6 mediated Mcl-1 upregulation in human multiple myeloma cells through the JAK/STAT3 rather than the MAPK pathway (Puthier et al., 1999a) . However, the results herein have con®rmed that a PI 3-K/ Akt-, but not STAT3 or MAPK, dependent pathway resulted mainly from IL-6-induced Mcl-1 up-regulation in human cervical cancer cells. This ®nding implies that the signaling pathways leading to the Mcl-1 induction may vary according to the type of cell models or stimuli employed. Our earlier studies and others (Chen et al., 1999; Qiu et al., 1998) have obtained similar results, showing that the PI 3-K/ Akt pathway is important for IL-6-induced Mcl-1 expression in human hepatoma and prostatic cancer cells. The PI 3-K/ Akt signaling pathway has recently attracted extensive attention because it may aect multiple cellular processes, including increasing cellular proliferation, inhibiting apoptosis and eventually facilitating tumorigenesis (Klippel et al., 1998; Tlsty, 1999) . Recently, PIK3CA has been shown to be an oncogene in cervical cancer (Ma et al., 2000) . Ampli®cation of PIK3CA may activate PI 3-K/ Akt signaling and contributes to cervical tumorigenesis.
Carcinogenesis involves an imbalance between the regulation of cell proliferation and apoptotic cell death. One related study has demonstrated that transformation of colorectal epithelium to adenomas and a b Figure 7 Anti-sense mcl-1 abolishes IL-6-mediated anti-cell death activity. (a) C33A/IL-6-c5 cells were transiently transfected with pCMV-GFP (1 mg/well) and either an empty expression control vector (pCDNA3), or a vector encoding antisense mcl-1 (4 mg/well). After 48 h of transfection, the medium was replaced with serum-free medium containing 3.5 mM doxorubicin for a further 24 h. Subsequently, cells were ®xed with 70% ethanol and GFP-positive cells in each ®eld (magni®ed 640) were quantitated under¯uorescence microscope. The results shown here represent the mean+s.d. of three independent experiments performed in duplicate. (b) The endogenous Mcl-1 level in C33A/IL-6-c5 cells was eectively reduced by anti-sense mcl-1. C33A/IL-6-c5 cells were transfected with anti-sense mcl-1 vector or control vector pCDNA3 for 48 h. After transfection, cell lysates were prepared and analysed by Western blotting using anti-Mcl-1 and antitubulin antibodies carcinomas is associated with progressive inhibition of apoptosis (Elder et al., 1996) . Supportive evidence from our previous study showed that suppression of apoptosis by overexpression of Bcl-2 promoted cellular mutagenesis and inhibited DNA repair . Therefore the IL-6-mediated Mcl-1-dependent anti-apoptotic eect should be an important mechanism for human cervical carcinogenesis. To the best of our knowledge, this is the ®rst work to demonstrate that IL-6 up-regulates the apoptotic threshold through a PI 3-K/ Akt-dependent up-regulation of Mcl-1, which may potentially in¯uence the oncogenesis of human cervical cancer.
Materials and methods

Tissues and cell culture
Human cervical cancer samples were obtained from surgical specimens of FIGO stage Ib-IIa uterine cervical cancer patients. The tumors were primary site cancers that had not been treated with chemotherapy or irradiation.
Tumor cell lines were obtained from the American Type Culture Collection (Rockville, MD, USA). The following were maintained in DMEM: C33A (carcinoma, cervix, human), SiHa (squamous carcinoma, cervix, human), Hela (epitheloid carcinoma, cervix, human), and MS-751 (epidermoid carcinoma, cervix, metastasis to lymph node, human). Meanwhile, HT-3 (carcinoma, cervix, metastasis to lymph node, human) was maintained in McCoy's 5a medium (Life Technologies, NY, USA). All of the culture mediums were supplemented with 10% (vol/vol) fetal bovine serum (FBS). The cell lines were cultured in a humidi®ed atmosphere of 5% CO 2 and 95% air at 378C.
Antibodies and reagents
Recombinant human IL-6, antibody to human IL-6, antibody to human bcl-2, and antibody to human Bcl-x L were obtained from R&D systems. Meanwhile, antibodies to human Mcl-1, human Bax, human IL-6 receptor a chain, and phospho-Erk, were from Santa Cruz Biotechnology. Antibodies to STAT, phospho-STAT, Akt and phospho-Akt were from Upstate Biotechnology. Furthermore, the kinase inhibitors, such as LY294002, and PD98059, were from Sigma. Meanwhile, mammalian expression plasmid for the dominant-negative mutant of STAT3, STAT3F, was kindly provided by Dr T Hirano (Nakajima et al., 1996) , while dominant-negative mutant of Akt vector was kindly donated by Dr RH Chen, at the Institute of Molecular Medicine, National Taiwan University, Taipei, Taiwan. Finally, the plasmid containing the antisense Mcl-1 was constructed as described previously (Jee et al., 2001) .
Immunohistochemical assay
Immunohistochemical analysis of Mcl-1, Bcl-2, and Bcl-x L proteins in tissue sections was performed as described previously (Krajewski et al., 1994) . Brie¯y, the slides were re-hydrated in PBS for 15 min and the endogenous peroxydase was inhibited by 3% H 2 O 2 /methanol for 10 min at room temperature. For blocking, 5% non-fat milk/PBS was used for 30 min at room temperature. Slides were incubated with either monoclonal anti-human Bcl-2 antibody, Bcl-x L antibody, or rabbit polyclonal anti-human Mcl-1 antibody at a 1 : 50 dilution for 16 h at 48C. The peroxidaseconjugated secondary antibody (Santa Cruz Biotechnology) were used in a 1 : 200 dilution and incubated for 1 h at room temperature. For all antibodies, staining was developed by immersing slides in 0.06% 3,3'-diaminobenzidine tetrahydrochloride (DAKO), followed by counterstaining with Gill's Hematoxylin V.
Enzyme immunoassay
The IL-6 levels of the cell culture supernatant were determined via enzyme immunoassay with commercially available kits (R&D Systems) according to the manufacturer's instructions. IL-6 measurements in the cell culture supernatant were taken twice, and the average value of IL-6 was recorded as pg/ml.
Immunoblotting
Cells were lysed in a lysis buer (1% Triton X-100, 150 mM NaCl, 1 mM EGTA, 1% NP-40, 1 mM NaF, 1 mM Na 3 VO 4 , 2 mM phenylmethyl-sulfonyl¯uoride (PMSF), 1 mg/ml aprotinin and leupeptin in PBS) and the tissue samples were homogenized in a lysis buer. The lysates were centrifuged at 12 000 r.p.m. for 25 min at 48C. Protein concentration was measured with a Bio-Rad protein assay (Hercules, CA, USA). A 50 mg protein sample was separated by 12.5% SDS ± PAGE, transferred onto polyvinylidene di¯uoride (PVDF) membrane, and immunoblotted with various antibodies. Bound antibodies were detected using appropriate peroxidase-coupled secondary antibodies, followed by an enhanced chemiluminescent detection system (ECL, Boehringer Mannheim).
Cell transfection and generation of stable cell lines
The pCMV-IL-6, a constitutive expression vector, carries 0.64 kb full-length human IL-6 cDNA under the control by the CMV promoter/enhancer sequence. The pCMV-IL-6 or pCMV was transfected into the C33A cell line with the TransFast TM transfection reagent (Promega). After 24 h, cells were replated in DMEM with 10% FBS and 600 mg/ml G418. Clones resistant to G418 were selected and expanded. The level of IL-6 and IL-6 receptor a chain of each clone was determined using enzyme immunoassay and Western blotting, respectively.
For transfection of dominant-negative Akt and dominantnegative STAT3, C33A cells (1610 6 ) were transfected with TransFast TM transfection reagent (Promega) according to manufacturer's instructions. For selecting stable clones, G418 was added to cultured medium 72 h after transfection.
Internucleosomal DNA fragmentation and nuclear condensation Morphological evaluation of apoptosis was performed by Hoechst staining. Brie¯y, the medium was gently removed at the indicated time to prevent the detachment of cells. Cells were ®xed with 4% formaldehyde in PBS for 5 min at room temperature, incubated with Hoechst dye 33258 at 5 mg/ml in PBS for 5 min, washed and ®nally mounted in PBS : glycerol (3 : 1). Fluorescent H33258-stained nuclei were observed with a¯uorescence microscope (Olympus, Japan).
Cell viability determined by MTT assay
Cells were plated into 96-well microplates at a density of 5610 3 cells/well for cell viability assay. Brie¯y, the cells were cultured at 378C for the indicated time, and 30 ml of MTT solution (5 mg/ml) was added into each well, then incubated for 4 h in darkness. The formazan grain was then dissolved in DMSO, and the absorbance at 570 nm was read using an ELISA plate reader.
Transient transfection and detection of cell viability
C33A/IL-6-c5 cells were plated 24 h before transfection at a density of 1610 5 cells/well in a 6-well plate. The cells were co-transfected with 2 mg green¯uorescent protein (GFP) expression vector and plasmid containing the antisense Mcl-1 (8 mg) or pCDNA3 control vector using the TransFast TM transfection reagent (Promega). Transfection was performed in duplicate. Twenty-four hours after transfection, the cell medium was replaced with a fresh serum-free medium for 24 h, and then treated with Doxorubicin (3.5 mM). Following 24 h treatment, cells were washed and ®xed in PBS containing 4% formaldehyde. These cells were washed twice with PBS and observed under a¯uorescence microscope. The GFP-positive cells in each well were then counted.
